NovaBay Pharmaceuticals (NBY) Competitors $1.36 -0.17 (-11.11%) As of 10/3/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NBY vs. AADI, ELUT, RNXT, SCYX, NBRV, LTRN, EGRX, ANVS, ESLA, and BRNSShould you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include Aadi Bioscience (AADI), Elutia (ELUT), RenovoRx (RNXT), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), Lantern Pharma (LTRN), Eagle Pharmaceuticals (EGRX), Annovis Bio (ANVS), Estrella Immunopharma (ESLA), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry. NovaBay Pharmaceuticals vs. Its Competitors Aadi Bioscience Elutia RenovoRx SCYNEXIS Nabriva Therapeutics Lantern Pharma Eagle Pharmaceuticals Annovis Bio Estrella Immunopharma Barinthus Biotherapeutics Aadi Bioscience (NASDAQ:AADI) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation. Which has better earnings & valuation, AADI or NBY? NovaBay Pharmaceuticals has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAadi Bioscience$25.07M1.93-$65.76M-$2.35-0.83NovaBay Pharmaceuticals$9.78M0.84-$9.64M-$53.72-0.03 Does the media prefer AADI or NBY? In the previous week, Aadi Bioscience's average media sentiment score of 0.00 equaled NovaBay Pharmaceuticals'average media sentiment score. Company Overall Sentiment Aadi Bioscience Neutral NovaBay Pharmaceuticals Neutral Which has more risk and volatility, AADI or NBY? Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Do analysts recommend AADI or NBY? NovaBay Pharmaceuticals has a consensus target price of $0.85, indicating a potential downside of 37.50%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NovaBay Pharmaceuticals is more favorable than Aadi Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in AADI or NBY? 52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 20.1% of NovaBay Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is AADI or NBY more profitable? NovaBay Pharmaceuticals has a net margin of -102.72% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aadi Bioscience-246.06% -71.87% -57.28% NovaBay Pharmaceuticals -102.72%-7,293.78%-158.41% SummaryAadi Bioscience beats NovaBay Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get NovaBay Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBY vs. The Competition Export to ExcelMetricNovaBay PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$8.17M$805.08M$6.13B$21.82BDividend YieldN/A4.84%5.67%3.54%P/E Ratio-0.031.2586.8829.82Price / Sales0.8425.40605.3267.55Price / CashN/A17.6437.9024.90Price / Book0.326.8512.554.60Net Income-$9.64M-$6.78M$3.31B$1.00B7 Day Performance-37.90%1.84%4.28%2.07%1 Month Performance-63.54%4.88%6.90%3.33%1 Year Performance91.55%45.15%70.54%13.11% NovaBay Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBYNovaBay Pharmaceuticals0.726 of 5 stars$1.36-11.1%$0.85-37.5%+91.5%$8.17M$9.78M-0.0330Positive NewsEx-DividendGap DownAADIAadi BioscienceN/A$1.90-1.0%N/A+1.0%$46.92M$25.07M-0.8340ELUTElutia3.2467 of 5 stars$1.09-2.3%$7.00+545.2%-76.8%$46.00M$24.38M-1.02180Gap DownHigh Trading VolumeRNXTRenovoRx1.7674 of 5 stars$1.26-3.5%$7.50+497.6%+29.4%$46.00M$40K-3.306High Trading VolumeSCYXSCYNEXIS0.792 of 5 stars$1.09-1.4%N/A-44.4%$45.48M$3.75M-2.7160News CoveragePositive NewsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070LTRNLantern Pharma2.0443 of 5 stars$4.14-0.6%$25.00+504.6%+9.0%$44.28MN/A-2.3020News CoverageEGRXEagle Pharmaceuticals1.4697 of 5 stars$3.37flatN/A+233.4%$43.77M$257.55M0.00100Gap DownANVSAnnovis Bio2.4517 of 5 stars$2.25-3.2%$17.33+672.1%-73.7%$43.66MN/A-1.103Analyst ForecastESLAEstrella Immunopharma2.5765 of 5 stars$1.17+0.9%$16.00+1,267.5%+12.9%$43.37MN/A-4.50N/AShort Interest ↓BRNSBarinthus Biotherapeutics2.5912 of 5 stars$1.08-2.3%$3.00+177.8%+8.7%$43.16M$14.97M-0.61107News CoverageShort Interest ↑ Related Companies and Tools Related Companies AADI Alternatives ELUT Alternatives RNXT Alternatives SCYX Alternatives NBRV Alternatives LTRN Alternatives EGRX Alternatives ANVS Alternatives ESLA Alternatives BRNS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NBY) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
